GlobeNewswire by notified

CASGEVY Gets Bahrain approval for treatment, marking it second country in the world

Share

MANAMA, Bahrain, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Bahrain has become the second country in the world and the first in the Middle East to approve the use of CASGEVY (exagamglogene autotemcel) for the treatment of patients with sickle cell disease and transfusion-dependent beta-thalassemia. The treatment was developed by Vertex Pharmaceuticals and CRISPR Therapeutics, after conducting a series of successful clinical trials in the UK, US, France, Italy, and Germany, among others.

Following the UK MHRA’s authorisation to use CASGEVY, Bahrain is the second country in the world and the first in the region to approve this treatment.

This extraordinary development opens up new possibilities for medical advancements and reinforces Bahrain's commitment to pioneering healthcare solutions, offering a better quality of life for patients with these blood disorders.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing technique that holds immense potential for treating a wide range of genetic disorders. By harnessing the power of CRISPR, scientists can transfuse patients with their own edited stem cells to produce fully functioning hemoglobin and offer hope for patients with conditions that were previously considered untreatable, such as sickle cell anemia. 

By embracing the revolutionary therapy, Bahrain is not only demonstrating its commitment to improving the health and well-being of its people but also positioning itself at the forefront of medical advancements in the region. 

Her Excellency, Dr Jaleela Jawad Minister of Health stated "This authorization showcases Bahrain's progressive approach to healthcare and its determination to remain at the forefront of scientific breakthroughs."

The confirmation of approval by the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain, followed thorough analysis and review undertaken by NHRA. Today, sickle-cell patients in Bahrain suffer from the very limited globally available options of treatment. Beyond bone marrow transplant, one of the only cures available for sickle cell disease is the use of genetic editing therapy, CASGEVY. 

Commenting on this, Dr. Ahmed Alansari CEO of the National Health Regulatory Authority in Bahrain said, “The approval of the use of CASGEVY in Bahrain marks a significant turning point in the cluster of treatments on offer to Bahrainis. It is a testament to the country's visionary leadership, dedication to innovation, and unwavering commitment to improving the lives of its citizens, while ushering in the highest quality of health care and wellbeing for them.”

For more information, please contact the National Communication Centre of the Kingdom of Bahrain on communication@ncc.gov.bh.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sparinvest SICAV ophæver suspension af handel med alle afdelinger26.2.2024 11:49:04 CET | pressemeddelelse

København, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Under henvisning til Nasdaq Copenhagens regler for udstedere af investeringsbeviser skal Sparinvest S.A. hermed på vegne af de berørte afdelinger i Sparinvest SICAV offentliggøre, at der igen kan foretages beregning af indre værdier for de pågældende afdelinger. De indre værdier er indberettet til Nasdaq Copenhagen. Suspension af handel med de berørte afdelinger ophæves hermed. Der er tale om følgende afdelinger: Fund NameISINOrder Book CodeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURRSustainable Corporate Bonds IG EUR RLU0264925727SSIGLIGEURRLong Danish Bonds DKK RLU0138507396SSILDBDKKRBalance EUR RLU0650088072SSIBAEURRBalance DKK RLU0673458609SSIBDKKRProcedo EUR RLU0139792278SSIPEURRProcedo DKK RLU0686499277SSIPDKKRSecurus EUR RLU0139791205SSISEURRSecurus DKK RLU0686498972SSISDKKRGlobal Convertible Bonds EUR RLU1438960566SSI

NNIT A/S: Reporting of transactions in NNIT’s shares made by person discharging managerial responsibilities26.2.2024 11:30:00 CET | Press release

NNIT has pursuant to article 19 of the Market Abuse Regulation received notification of transactions by person with managerial responsibilities in NNIT. Reference is made to the attached table showing detailed information about the transactions. Contact for further information Carsten Ringius EVP & CFO Tel: +45 3077 8888 carr@nnit.com Media relations Tina Joanne Hindsbo Media Relations Manager Tel: +45 3077 9578 tnjh@nnit.com NNIT is a leading provider of IT solutions to life sciences internationally, and to the public and enterprise sectors in Denmark We focus on high complexity industries and thrive in environments where regulatory demands and complexity are high. We advise and build sustainable digital solutions that work for the patients, citizens, employees, end users or customers. We strive to build unmatched excellence in the industries we serve, and we use our domain expertise to represent a business first approach – strongly supported by a selection of partner technologies, bu

Ekstraordinære indfrielser (CK93) - Nykredit Realkredit A/S26.2.2024 11:22:00 CET | pressemeddelelse

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Nykredit Realkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 23. Februar 2024 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Nykredit Realkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Nykredit Realkredit A_S - 26-02-2024XMLeordindf

Prepayments (CK93) - Nykredit Realkredit A/S26.2.2024 11:22:00 CET | Press release

To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 23 February 2024 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Nykredit Realkredit A/S Attachments Prepayments - Nykredit Realkredit A_S - 26-02-2024XMLeordindf

Ekstraordinære indfrielser (CK93) - Totalkredit A/S26.2.2024 11:22:00 CET | pressemeddelelse

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 23. februar 2024 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Totalkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Totalkredit A_S-26-02-2024XML_eordindftk

HiddenA line styled icon from Orion Icon Library.Eye